The Quadrant, a 75,316 sq. ft campus which comprises four terraces of office and laboratory buildings, was acquired from Addington Capital, an investment management firm, for £13.475 million and a net yield of 6.7 per cent. As part of the deal, Kadans also bought 1.59 acres of land with planning permission for another 20,000 sq. ft of lab and office space.
Bidwells alongside Creative Places to secure the deal, which is Kadans’ first since being bought by AXA IM – Real Assets at the end of last year.
Located on Abingdon Science Park, a highly regarded research and development location that benefits from close proximity to other similar hubs in Oxford – such as Milton Park and Harwell Campus – The Quadrant is home to a number of science and technology companies, including PsiOxus Therapeutics, a world-leading cancer gene therapy company, and Tessella, a data science firm.
The Quadrant is located six miles south of Oxford and is just 63 miles north west of London. Oxford and Didcot Parkway train stations both sit less than nine miles from Abingdon. London, another hub of UK life sciences, is reachable in just 45 minutes by train.
Oxford is part of the Oxford-Cambridge Arc innovation cluster, which according to Bidwells’ own estimates, could be worth £400 billion to the UK economy annually by 2050. The region’s knowledge-based economy, which has a critical mass in Oxford and Cambridge, is crucial to UK plc’s role as a global exporter of scientific and technological innovation post-Brexit.
Saul Western, partner, capital markets at Bidwells, said: “Bidwells are happy to have helped Kadans Science Partner acquire this scheme and grow its platform in the UK. The Quadrant at Abingdon Science Park sits amongst the long-established science and technology cluster around Oxford which is enjoying an exciting period of growth as part of the Oxbridge Arc. This demonstrates investors’ deepening interest to secure exposure to this region and the UK’s science and tech sector.”.